Stock A298380 ABL BIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings ABL Bio Inc.

Equities

A298380

KR7298380007

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
26,400 KRW +6.45% Intraday chart for ABL Bio Inc. +14.53% +7.32%
Mar. 25 Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates CI
2023 ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ABL BIO INC. Stock ABL Bio Inc.
+7.32% 919M - -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.63% 102B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.62% 96.29B
B+
ARGENX SE Stock argenx SE
+1.89% 22.18B
B
BIONTECH SE Stock BioNTech SE
-16.67% 21.2B
B+
GENMAB A/S Stock Genmab A/S
-8.45% 18.31B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 17.38B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.41% 13.97B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.57% 12.17B
C+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. A298380 Stock
  4. Ratings ABL Bio Inc.